The FDA has given the green light for a 12.5-mg dose of the long-acting injectable formulation of risperidone, Risperdal Consta, from Alkermes and Janssen.
The FDA has given the green light for a 12.5-mg dose of the long-acting injectable formulation of risperidone, Risperdal Consta, from Alkermes and Janssen. The new dosage is scheduled to be available by May 1 and is approved for the treatment of schizophrenia. Risperdal Consta, which is given by injection every two weeks, was previously available in 25-mg, 37.5-mg, and 50-mg dose units.
To see more Hot off the Press news articles, click here.
